<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vitamin K supplementation for cystic fibrosis - Jagannath, VA - 2020 | Cochrane Library</title> <meta content="Vitamin K supplementation for cystic fibrosis - Jagannath, VA - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008482.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vitamin K supplementation for cystic fibrosis - Jagannath, VA - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008482.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008482.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Vitamin K supplementation for cystic fibrosis" name="citation_title"/> <meta content="Vanitha A Jagannath" name="citation_author"/> <meta content="American Mission Hospital" name="citation_author_institution"/> <meta content="kidzdoc311@gmail.com" name="citation_author_email"/> <meta content="Vidhu Thaker" name="citation_author"/> <meta content="Columbia University Medical Center" name="citation_author_institution"/> <meta content="Anne B Chang" name="citation_author"/> <meta content="Menzies School of Health Research, Charles Darwin University" name="citation_author_institution"/> <meta content="Amy I Price" name="citation_author"/> <meta content="Empower 2 Go" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD008482.pub6" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/06/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008482.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008482.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008482.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Biomarkers [blood]; Blood Coagulation [drug effects]; Bone Density; Cystic Fibrosis [*blood, complications]; Dietary Supplements; Fractures, Bone [prevention &amp; control]; Osteocalcin [blood]; Osteogenesis [*drug effects]; Protein Precursors [blood]; Prothrombin; Quality of Life; Randomized Controlled Trials as Topic; Vitamin K [*administration &amp; dosage, blood]; Vitamin K Deficiency [complications, *drug therapy]; Vitamins [*administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008482.pub6&amp;doi=10.1002/14651858.CD008482.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008482\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008482\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ko","ms","ja","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008482.pub6",title:"Vitamin K supplementation for cystic fibrosis",firstPublishedDate:"Jun 4, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008482.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008482.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008482.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008482.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008482.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008482.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008482.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008482.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008482.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008482.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3230 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008482.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/appendices#CD008482-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/supinfo/CD008482StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/supinfo/CD008482StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vitamin K supplementation for cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/information#CD008482-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Vanitha A Jagannath</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/information#CD008482-cr-0005">Vidhu Thaker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/information#CD008482-cr-0006">Anne B Chang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008482.pub6/information#CD008482-cr-0007">Amy I Price</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/information/en#CD008482-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 June 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008482.pub6">https://doi.org/10.1002/14651858.CD008482.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008482-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008482-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008482-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008482-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008482-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008482-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008482-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008482-abs-0001" lang="en"> <section id="CD008482-sec-0001"> <h3 class="title" id="CD008482-sec-0001">Background</h3> <p>Malabsorption and deficiency of fat‐soluble vitamins K may occur in cystic fibrosis, a genetic disorder affecting multiple organs. Vitamin K is known to play an important role in both blood coagulation and bone formation, hence the role of supplementation of vitamin K in this category needs to be reviewed. This is an updated version of the review. </p> </section> <section id="CD008482-sec-0002"> <h3 class="title" id="CD008482-sec-0002">Objectives</h3> <p>To assess the effects of vitamin K supplementation in people with cystic fibrosis and to investigate the hypotheses that vitamin K will decrease deficiency‐related coagulopathy, increase bone mineral density, decrease risk of fractures and improve quality of life in people with CF. Also to determine the optimal dose and route of administration of vitamin K for people with CF (for both routine and therapeutic use). </p> </section> <section id="CD008482-sec-0003"> <h3 class="title" id="CD008482-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. </p> <p>Most recent search: 12 August 2019.</p> </section> <section id="CD008482-sec-0004"> <h3 class="title" id="CD008482-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of all preparations of vitamin K used as a supplement compared to either no supplementation (or placebo) at any dose or route and for any duration, in patients with cystic fibrosis. </p> </section> <section id="CD008482-sec-0005"> <h3 class="title" id="CD008482-sec-0005">Data collection and analysis</h3> <p>Two authors independently screened papers, extracted trial details and assessed their risk of bias. The quality of the evidence was assessed using the GRADE criteria. </p> </section> <section id="CD008482-sec-0006"> <h3 class="title" id="CD008482-sec-0006">Main results</h3> <p>Three trials (total 70 participants, aged 8 to 46 years) assessed as having a moderate risk of bias were included. One trial compared vitamin K to placebo, a second to no supplementation and the third compared two doses of vitamin K. No trial in either comparison reported our primary outcomes of coagulation and quality of life or the secondary outcomes of nutritional parameters and adverse events. </p> <p>Vitamin K versus control </p> <p>Two trials compared vitamin K to control, but data were not available for analysis. One 12‐month trial (n = 38) compared 10 mg vitamin K daily or placebo in a parallel design and one trial (n = 18) was of cross‐over design with no washout period and compared 5 mg vitamin K/week for four‐weeks to no supplementation for four‐weeks. Only the 12‐month trial reported on the primary outcome of bone formation; we are very uncertain whether vitamin K supplementation has any effect on bone mineral density at the femoral hip or lumbar spine (very low‐quality evidence). Both trials reported an increase in serum vitamin K levels and a decrease in undercarboxylated osteocalcin levels. The cross‐over trial also reported that levels of proteins induced by vitamin K absence (PIVKA) showed a decrease and a return to normal following supplementation, but due to the very low‐quality evidence we are not certain that this is due to the intervention. </p> <p>High‐dose versus low‐dose vitamin K </p> <p>One parallel trial (n = 14) compared 1 mg vitamin K/day to 5 mg vitamin K/day for four weeks. The trial did report that there did not appear to be any difference in serum undercarboxylated osteocalcin or vitamin K levels (very low‐quality evidence). While the trial reported that serum vitamin K levels improved with supplementation, there was no difference between the high‐dose and low‐dose groups. </p> </section> <section id="CD008482-sec-0007"> <h3 class="title" id="CD008482-sec-0007">Authors' conclusions</h3> <p>There is very low‐quality evidence of any effect of vitamin K in people with cystic fibrosis. While there is no evidence of harm, until better evidence is available the ongoing recommendations by national CF guidelines should be followed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008482-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008482-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008482-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008482-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008482-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008482-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008482-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008482-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008482-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008482-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008482-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008482-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008482-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008482-abs-0002" lang="en"> <h3>Vitamin K supplementation for cystic fibrosis</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence to see whether supplementing vitamin K in people with cystic fibrosis counteracts the effects of deficiency on blood clotting, bone strength and quality of life in people with cystic fibrosis. We tried to determine the best dose needed to prevent this deficiency. This is an update of an earlier review. </p> <p><b>Background</b> </p> <p>Cystic fibrosis is an inherited condition which causes disease, most noticeably in the lungs, digestive system and pancreas. In people with cystic fibrosis, the pancreas often does not produce enough enzymes to allow the body to absorb digested food properly and this may also be linked to deficiencies of fat‐soluble vitamins like vitamin K. Vitamin K is needed for adequate blood clotting, bone formation and some metabolic functions. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 12 August 2019.</p> <p><b>Study characteristics</b> </p> <p>We included three trials (total of 70 participants aged between 8 and 46 years) in the review. </p> <p>Two trials compared vitamin K to a control. In the first trial all 18 people taking part (aged 13 to 35 years) were given 5 mg oral vitamin K supplement once a week or nothing for a total duration of one month and then they swapped to the other group for another month. Unfortunately, we could not analyse the data from this trial because the investigators did not report data just from the first part of the trial (only from the end of the trial when everyone taking part had been in both groups), so we could not tell if the effects were due to supplements or no supplements. In the second trial a total of 38 people aged 16 to 45 years took part. They were given either 10 mg vitamin K or placebo (a dummy supplement not containing any vitamin K) every day for 12 months, but the investigators did not state how many people were in each group so we could not analyse the results. </p> <p>In the third trial (14 children aged 8 to 18 years old) participants were given oral vitamin K supplements, half of them at a dose of 1 mg every day and the other half were given 5 mg every day for one month. </p> <p><b>Key results</b> </p> <p>No trial in either comparison reported our primary outcomes of blood clotting and quality of life or the secondary measures of nutrition and adverse events. </p> <p>Vitamin K versus control </p> <p>Only the 12‐month trial reported on the primary outcome of bone formation; we are very uncertain whether vitamin K supplementation has any effect on bone mineral density measured at the hip or lower back (very low‐quality evidence). Both trials reported an increase in vitamin K levels in the blood and a decrease in undercarboxylated osteocalcin levels (this is an indicator of the risk of hip fracture). The four‐week trial also reported that levels of proteins induced by vitamin K absence (PIVKA) dropped and returned to normal levels, but due to the very low‐quality evidence we are not certain that this is due to supplementation. </p> <p>High‐dose versus low‐dose vitamin K </p> <p>The trial reported that while vitamin K levels improved there did not seem to be any difference between the high‐dose and low‐dose groups. There also did not seem to be any difference in undercarboxylated osteocalcin levels (very low‐quality evidence). </p> <p><b>Quality of the evidence</b> </p> <p>The overall quality of the evidence was judged to be very low due to risks of bias in the design of all trials and the low numbers of participants. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008482-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008482-sec-0094"></div> <h3 class="title" id="CD008482-sec-0095">Implications for practice</h3> <section id="CD008482-sec-0095"> <p>People with cystic fibrosis (CF) are at risk of vitamin K deficiency. Routine supplementation along with the other fat‐soluble vitamins is common clinical practice; however, there appears to be very little consensus about the exact dosage that should be prescribed. Until further evidence is available supplementation should continue to follow published European Cystic Fibrosis Society and Cystic Fibrosis Foundation guidelines (<a href="./references#CD008482-bbs2-0014" title="BorowitzD , BakerRD , StallingsV . Consensus report on nutrition for paediatric patients with cystic fibrosis. Journal of Pediatric Gastroenterology &amp; Nutrition2002;35:246-59.">Borowitz 2002</a>; <a href="./references#CD008482-bbs2-0016" title="Cystic Fibrosis Trust Nutrition Working Group. Nutritional management of cystic fibrosis. London: Cystic Fibrosis Trust2002.">Cystic Fibrosis Trust 2002</a>; <a href="./references#CD008482-bbs2-0043" title="SinaasappelM , SternM , LittlewoodJ , WolfeS , SteinkampG , HeijermanHG , et al. Nutrition in patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis2002;1(2):51-75. [PMID: 15463811]">Sinaasappel 2002</a>) and be guided by monitoring of the proteins induced by vitamin K absence (PIVKA) or undercarboxylated osteocalcin levels at annual clinical reviews. </p> </section> <h3 class="title" id="CD008482-sec-0096">Implications for research</h3> <section id="CD008482-sec-0096"> <p>There is now a better understanding of the important effect of vitamin K on gamma‐carboxylation of osteocalcin synthesized in the bones over and above its well‐acknowledged requirement for synthesis of coagulation proteins in the liver. Well‐designed randomised controlled trials are still needed to determine the impact of vitamin K on the outcomes relevant to bone health in addition to routine supplementation and its benefits in people with CF. Research in this area is currently limited and long‐term and large‐scale trials are needed to provide clear answers to these issues. Additional issues that need to be considered are the sensitivity and reliability of markers for vitamin K deficiency, as well as the diagnostic accuracy and associated costs of laboratory equipment and tests. </p> <p>Thus randomised controlled trials of vitamin K supplementation should be placebo‐controlled trials of parallel‐design involving both children and adults (considered separately). Outcomes should include clinical measures (e.g. coagulation effects), bone measures (density scans) and biochemical markers. In addition patient‐orientated measures such as quality of life and patient satisfaction should also be evaluated. Possible adverse events should also be specifically recorded and reported. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008482-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008482-sec-0008"></div> <div class="table" id="CD008482-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vitamin K compared to control for people with cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vitamin K compared to control for people with cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with cystic fibrosis<br/><b>Setting</b> : community or health care facilities<br/><b>Intervention</b> : vitamin K<br/><b>Comparison</b>: placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Vitamin K</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to cessation of bleeding</b> </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bone mineral density</b>: lumbar spine z score </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The mean (SD) change in the placebo group in z score at the lumbar spine was 0.041 (0.15) g/cm³ and in the treatment group it was ‐0.073 (0.30) g/cm³. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> <p>⊕⊝⊝⊝<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors also reported mean change in z score in those participants 25 or under and those that were over 25 years. They concluded that vitamin K had no significant effect except in participants that were over 25 years. where vitamin K may have a protective effect against decline in BMD (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> <p>The mean (SD) change in the placebo group at the femoral hip z score was 0.053 (0.19) g/cm³ and in the treatment group was ‐0.20 (0.31) g/cm³. The mean change in femoral hip z score ≤ 25, but there is not enough information to comment on the statistical significance of this. </p> <p>The authors report no significant effect of vitamin K on bone mineral density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b>: CFQ‐R </p> <p><b>Follow‐up</b>:12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b>: CFQoL </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PIVKA II levels</b>: change in PIVKA II (ng/mL) </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Mean (SD) PIVKA‐II concentrations increased significantly when participants were not supplemented (5.1 (3.2) ng/mL in the supplemented group and 21.8 (3.2) ng/mL in the unsupplemented group) and almost one third (5 out of 18) of the participants had PIVKA‐II levels within the normal range (≤ 2 ng/mL) following supplementation. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> <p>⊕⊝⊝⊝<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Uncarboxylated osteocalcin</b>: </p> <p>change in carboxylation of osteocalcin (% Glu‐OC)</p> <p><b>Follow‐up</b>: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies (total n = 56) narratively reported that vitamin K improved carboxylation of osteocalcin (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI</b> : confidence interval; <b>CFQoL</b> : Cystic Fibrosis Quality of Life; <b>CFQ‐R</b> : Cystic Fibrosis Questionnaire ‐ Revised; <b>PIVKA‐II</b> : proteins induced by vitamin K absence; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty</b> : our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate.The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice due to an unclear risk of bias in one RCT, particularly for the domains of randomisation, allocation concealment and blinding. </p> <p><sup>b</sup> Downgraded once due to imprecision as numbers were too low to meet the optimal information size. </p> <p><sup>c</sup> Downgraded twice due to risk of bias within one RCT. The randomisation and allocation concealment processes were unclear and it wasn't possible to blind either participants or healthcare providers. It was unclear whether the outcome assessors were blinded. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008482-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Comparison of different vitamin K doses for people with cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High‐dose vitamin K compared to low‐dose vitamin K for people with cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with cystic fibrosis<br/><b>Setting</b> : community or health care facilities<br/><b>Intervention</b> : high‐dose vitamin K<br/><b>Comparison</b>: low‐dose vitamin K </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with low‐dose vitamin K</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with high‐dose vitamin K</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to cessation of bleeding</b> </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bone mineral density</b>: lumbar spine z score </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b>: CFQ‐R </p> <p><b>Follow‐up</b>:12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b>: CFQoL </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PIVKA II levels</b>: change in PIVKA II (ng/mL) </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Uncarboxylated osteocalcin</b>: </p> <p>change in carboxylation of osteocalcin level (% Glu‐OC)</p> <p><b>Follow‐up</b>: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Uncarboxylated osteocalcin was 2.20% lower in the 1 mg group than in the 5 mg group (14.33% lower to 9.93% higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> <p>⊕⊝⊝⊝<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI</b> : confidence interval; <b>CFQoL</b> : Cystic Fibrosis Quality of Life; <b>CFQ‐R</b> : Cystic Fibrosis Questionnaire ‐ Revised; <b>PIVKA‐II</b> : proteins induced by vitamin K absence; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty</b> : our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate.The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once due to imprecision as numbers were too low to meet the optimal information size. </p> <p><sup>b</sup> Downgraded twice due to risk of bias within the single RCT. There was an unclear risk of bias across four of the six domains, particularly around randomisation, allocation conclealment and blinding. This was a cross‐over trial with no wash‐out period and there was therefore a potential carry‐over of treatment effect. No first‐period data were available. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008482-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008482-sec-0009"></div> <section id="CD008482-sec-0010"> <h3 class="title" id="CD008482-sec-0010">Description of the condition</h3> <p>Cystic fibrosis (CF) is a multisystem disorder that primarily affects the respiratory and gastrointestinal (GI) systems (<a href="./references#CD008482-bbs2-0032" title="MorganWJ , ButlerSM , JohnsonCA , ColinAA , FitzSimmonsSC , GellerDE , et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatric Pulmonology1999;28(4):231-41.">Morgan 1999</a>). It is caused by homozygous presence of a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. </p> <p>In the UK there are over 8000 people affected by CF and in the United States of America this figure is approximately 30,000; and over 100,000 people worldwide, most are diagnosed by six months of age and the median survival has reached the fifth decade of life (<a href="./references#CD008482-bbs2-0018" title="DavisPB . Cystic fibrosis since 1938. American Journal of Respiratory and Critical Care Medicine2006;173(5):475-82. [PMID: 16126935]">Davis 2006</a>; <a href="./references#CD008482-bbs2-0025" title="GossCH , RosenfeldM . Update on Cystic Fibrosis Epidemiology. Current Opinion in Pulmonary Medicine2004;10(6):510-4. [PMID: 15510059]">Goss 2004</a>; <a href="./references#CD008482-bbs2-0028" title="KlimovaB , KucaK , NovotnyM , MaresovaP . Cystic fibrosis revisited - a review study. Medicinal Chemistry (Shariqah (United Arab Emirates))2017;13(2):102-9. [PMID: 27292156]">Klimova 2017</a>; <a href="./references#CD008482-bbs2-0044" title="StaabD . Cystic fibrosis - therapeutic challenge in cystic fibrosis children. European Journal of Endocrinology / European Federation of Endocrine Societies2004;151 Suppl 1:S77-80. [PMID: 15339249]">Staab 2004</a>). It is the most common, life‐threatening, autosomal‐recessively inherited disease in the white population, with a carrier rate of 1 in 25 and an incidence of 1 in 2500 live births (<a href="./references#CD008482-bbs2-0038" title="RatjenF , DöringG . Cystic fibrosis. Lancet2003;361(9358):681-9.">Ratjen 2003</a>); CF is less common in other ethnic groups, approximately 1 in 46 Hispanics, 1 in 65 Africans and 1 in 90 Asians carry at least one abnormal CFTR gene (<a href="./references#CD008482-bbs2-0013" title="BobadillaJL , Macek M Jr, FineJP , FarrellPM . Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Human Mutation2002;19(6):575-606.">Bobadilla 2002</a>; <a href="./references#CD008482-bbs2-0031" title="KrzyzanowskaP , Drzymala-CzyzS , RohovykN , BoberL , MoczkcoJ , RachelM , et al. Prevalence of vitamin K deficiency and associated factors in non-supplemented cystic fibrosis patients [Prevalencia de deficiencia de vitamina K y factores asociados en pacientes con fibrosis quistica sin aporte suplementario.]. Archivos argentinos de pediatria2018;116(1):e19-25. [PMID: 29333815]">Krzyzanowska 2018</a>). </p> <p>The CFTR protein is a chloride ion channel, important in tissues that produce sweat, digestive juices and mucus. The dominant symptoms of CF relate to the respiratory and GI systems (<a href="./references#CD008482-bbs2-0048" title="WagenerJS , HeadleyAA . Cystic fibrosis: current trends in respiratory care. Respiratory Care2003;48(3):234-45.">Wagener 2003</a>). In the GI system, liver dysfunction, intestinal obstruction and exocrine pancreatic insufficiency are the most common morbidities. Pancreatic insufficiency (PI) affects up to 90% of people with CF and causes fat malabsorption (<a href="./references#CD008482-bbs2-0020" title="DodgeJA , TurckD . Cystic fibrosis: nutritional consequences and management. Best Practice &amp; Research. Clinical Gastroenterology2006;20(3):531-46.">Dodge 2006</a>). Fat‐soluble vitamins (A, D, E and K) are co‐absorbed with fat and thus deficiency of these vitamins may occur (<a href="./references#CD008482-bbs2-0020" title="DodgeJA , TurckD . Cystic fibrosis: nutritional consequences and management. Best Practice &amp; Research. Clinical Gastroenterology2006;20(3):531-46.">Dodge 2006</a>). Hence, vitamin K deficiency is well‐recognised in people with CF and PI. While deficiencies may occur from the disease process of CF and from insufficient supplementation, another additional co‐factor is the long‐term use of certain types of antibiotics. These can put some individuals at additional risk of vitamin K deficiency by altering intestinal flora which produce vitamin K (<a href="./references#CD008482-bbs2-0015" title="ConwaySP , WolfeSP , BrownleeKG , WhiteH , OldroydB , TruscottJG , et al. Vitamin K status among children with cystic fibrosis and its relationship to bone mineral density and bone turnover. Pediatrics2005;115(5):1325-31.">Conway 2005</a>). Long‐term effects of bowel resection, an intervention required for intestinal obstruction in some newborns with CF, and varying degrees of liver dysfunction can pose a further additional risk for vitamin K deficiency (<a href="./references#CD008482-bbs2-0023" title="FuchsJR , LangerJC . Long-term outcome after neonatal meconium obstruction. Pediatrics1998;101(4):E7. [PMID: 9521973]">Fuchs 1998</a>). </p> <p>The manifestations of vitamin K deficiency can range from a mild subclinical identification (e.g. low levels of vitamin K in the blood) to widespread coagulopathy (defect in the body's mechanism for blood clotting). Such manifestations may include mucosal bleeding (e.g. in the nose, gastro‐intestinal system, and in the urine) and subcutaneous bleeding (e.g. oozing from venipuncture sites and susceptibility to bruising). Vitamin K is also involved in the calcium binding proteins in the bone and its deficiency is implicated in defective bone remineralization and reduced bone mineral density (BMD) and thus osteopenia and osteoporosis (<a href="./references#CD008482-bbs2-0015" title="ConwaySP , WolfeSP , BrownleeKG , WhiteH , OldroydB , TruscottJG , et al. Vitamin K status among children with cystic fibrosis and its relationship to bone mineral density and bone turnover. Pediatrics2005;115(5):1325-31.">Conway 2005</a>). </p> <p>The majority of CF centres routinely administer vitamins A, D, and E as supplements from the neonatal period. Vitamin K administration is usually prescribed when clinical deficiencies are detected or following routine investigations. The limited storage capacity and rapid metabolic turnover of vitamin K (<a href="./references#CD008482-bbs2-0034" title="OlsonRE . Vitamin K. In: ShilsME , OlsonJA , ShikeM , editors(s). Modern Nutrition in Health and Disease. 8th edition. Baltimore: Williams and Wilkins, 1994:343-58.">Olsen 1994</a>) supports the recommendations for daily rather than weekly supplementation of vitamin K (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). </p> </section> <section id="CD008482-sec-0011"> <h3 class="title" id="CD008482-sec-0011">Description of the intervention</h3> <p>Two forms of vitamin K (K1 and K2) occur naturally and synthetic forms of the vitamin (K3, K4, and K5) are also available. Naturally occurring vitamin K is found in green vegetables, i.e. kale, collards, spinach and salads (K1‐phytonadione) and a small amount is made in human gut by bacteria (K2‐menaquinones). Therapeutic vitamin K is available in both water‐soluble and insoluble forms (<a href="./references#CD008482-bbs2-0022" title="DuriePR . Vitamin K and the management of patients with cystic fibrosis. CMAJ1994;151(7):933-6. [PMID: 7922929]">Durie 1994</a>). The enteral forms of vitamin K supplementation are commonly prescribed. These can be in tablet, ampoule (<a href="./references#CD008482-bbs2-0014" title="BorowitzD , BakerRD , StallingsV . Consensus report on nutrition for paediatric patients with cystic fibrosis. Journal of Pediatric Gastroenterology &amp; Nutrition2002;35:246-59.">Borowitz 2002</a>; <a href="./references#CD008482-bbs2-0017" title="UK CF Trust. Bone Mineralisation in Cystic Fibrosis.Report of the UK Cystic Fibrosis Trust Bone Mineralisation Working Group. www.cftrust.org.uk/aboutcf/publications/consensusdoc/Bone-Mineral-Booklet.pdf February 2007.">Cystic Fibrosis Trust 2007</a>) or multivitamin preparations (<a href="./references#CD008482-bbs2-0022" title="DuriePR . Vitamin K and the management of patients with cystic fibrosis. CMAJ1994;151(7):933-6. [PMID: 7922929]">Durie 1994</a>). Vitamin K can also be administered by intramuscular (<a href="./references#CD008482-bbs2-0042" title="ShearerMJ . Vitamin K. Lancet1995;345(8944):229-34. [PMID: 7823718]">Shearer 1995</a>) or intravenous injections (<a href="./references#CD008482-bbs2-0047" title="VergheseT , BeverleyD . Vitamin K deficient bleeding in cystic fibrosis. Archives of Disease in Childhood2003;88(6):553. [PMID: 12765934]">Verghese 2003</a>). </p> </section> <section id="CD008482-sec-0012"> <h3 class="title" id="CD008482-sec-0012">How the intervention might work</h3> <p>Vitamin K functions as the cofactor of the enzyme vitamin K‐dependent carboxylase. This enzyme catalyses the post‐translation formation of gamma‐carboxyglutamyl (Gla) residues in specific proteins. Vitamin K‐dependent proteins are: blood coagulation factors (prothrombin and Factors VII, IX and X); other plasma proteins (protein C, protein S and protein Z); two proteins from bone (osteocalcin and matrix Gla‐protein); and proteins from lung, kidney, spleen, testis, placenta and other tissues (<a href="./references#CD008482-bbs2-0046" title="UotilaL . The metabolic functions and mechanism of action of vitamin K. Scandinavian Journal of Clinical and Laboratory Investigation1990;201 Suppl:109-17. [PMID: 2244179]">Uotila 1990</a>). </p> <p>Blood coagulation requires activation of inactive proenzymes; hence, vitamin K is a vital factor in synthesis of clotting factors and causes haemostasis in vitamin K‐dependant bleeding manifestations. </p> <p>Vitamin K‐related carboxylation allows the activation of the bone matrix protein, osteocalcin, resulting in osteoblast function and bone formation; vitamin K deficiency impairs this process and thus impairs bone formation (<a href="./references#CD008482-bbs2-0033" title="OkanoT . Vitamin D, K and bone mineral density. Clinical Calcium2005;15(9):1489-94. [PMID: 16137948]">Okano 2005</a>). </p> </section> <section id="CD008482-sec-0013"> <h3 class="title" id="CD008482-sec-0013">Why it is important to do this review</h3> <p>Vitamin K deficiency is common in people with CF with pancreatic insufficiency. In a recent study of people with CF, the pathological proteins induced by vitamin K absence (PIVKA)‐II concentration (≥ 2 ng/mL) was found in 42.8% of the population studied and an abnormal percentage of osteocalcin (≥ 20%) in 35.7% of people studied (<a href="./references#CD008482-bbs2-0030" title="KrzyzanowskaP , PogorzelskiA , SkorupaW , MoczkoJ , GrebowiecP , WalkowiakJ . Exogenous and endogenous determinants of vitamin K status in cystic fibrosis. Scientific Reports2015;5:12000. [DOI: 10.1038/srep12000] [PMID: 26160248]">Krzyzanowska 2015</a>). Supplementation (often oral and occasionally parenteral) appears to be the most immediate measure to address the deficiency, although there is limited consensus on the dose and frequency of supplements for routine or therapeutic use (<a href="./references#CD008482-bbs2-0037" title="RashidM , DurieP , AndrewM , KalninsD , ShinJ , CoreyM , et al. Prevalence of vitamin K deficiency in cystic fibrosis. American Journal of Clinical Nutrition1999;70(3):378–82.">Rashid 1999</a>). In 1992 the Consensus Committee of the Cystic Fibrosis Foundation (CFF) suggested a particular dosage (<a href="./references#CD008482-bbs2-0036" title="RamseyBW , FarrellPM , PencharzP , and the Consensus Committee. Nutritional assessment and management in cystic fibrosis: a consensus report. American Journal of Clinical Nutrition1992;55(1):108-16.">Ramsey 1992</a>); but the recommendations were later proved ineffectual by another study (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). The 2002 American Consensus Committee recommended a low‐dose supplementation of vitamin K for all ages (0.3 to 0.5 mg/day), but emphasized that no adverse effects had been reported at any dosage level of vitamin K (<a href="./references#CD008482-bbs2-0014" title="BorowitzD , BakerRD , StallingsV . Consensus report on nutrition for paediatric patients with cystic fibrosis. Journal of Pediatric Gastroenterology &amp; Nutrition2002;35:246-59.">Borowitz 2002</a>). Recent recommendations from Europe and the UK have suggested varying dose regimens ranging from 0.3 to 1 mg/day to 10 mg/week (<a href="./references#CD008482-bbs2-0016" title="Cystic Fibrosis Trust Nutrition Working Group. Nutritional management of cystic fibrosis. London: Cystic Fibrosis Trust2002.">Cystic Fibrosis Trust 2002</a>; <a href="./references#CD008482-bbs2-0043" title="SinaasappelM , SternM , LittlewoodJ , WolfeS , SteinkampG , HeijermanHG , et al. Nutrition in patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis2002;1(2):51-75. [PMID: 15463811]">Sinaasappel 2002</a>). There is a suggestion from one study that only a higher level of supplementation can normalise vitamin K levels in people with CF (<a href="./references#CD008482-bbs2-0021" title="DoughertyKA , SchallJI , StallingsVA . Suboptimal vitamin K status despite supplementation in children and young adults with cystic fibrosis. American Journal of Clinical Nutrition2010;92(3):660-7. [PMID: 20554788]">Dougherty 2010</a>). Another study found that vitamin K deficiency occurs in people with CF despite applied supplementation (<a href="./references#CD008482-bbs2-0029" title="KrzyzanowskaP , LisowskaA , SkorupaW , PogorzelskiA , KaminskaB , CichyW , et al. Vitamin K deficiency in patients with CF despite supplementation [Niedobor witaminy K u chorych na mukowiscydoze pomimo stosowanej suplementacji]. Medycyna Wieku Rozwojowego2010;14(1):68-72. [PMID: 20608431]">Krzyzanowska 2010</a>). The study authors suggested that an accurate supplementation dose should be estimated individually and the assessment of its effectiveness requires studies allowing investigators to determine the real body resources of vitamin K. </p> <p>There is no uniform consensus on routine or at‐risk vitamin K supplementation in individuals with CF. There is increasing evidence that the prevalence of vitamin K deficiency in CF is associated with an increased morbidity (<a href="./references#CD008482-bbs2-0037" title="RashidM , DurieP , AndrewM , KalninsD , ShinJ , CoreyM , et al. Prevalence of vitamin K deficiency in cystic fibrosis. American Journal of Clinical Nutrition1999;70(3):378–82.">Rashid 1999</a>). Thus, a systematic review on vitamin K supplementation in people with CF could provide evidence to guide clinical practice. </p> <p>This is an update of previous review versions (<a href="./references#CD008482-bbs2-0050" title="Jagannath VA, FedorowiczZ , ThakerV , ChangAB , Al-HarthyN . Vitamin K supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD008482]">Jagannath 2010</a>; <a href="./references#CD008482-bbs2-0051" title="JagannathVA , FedorowiczZ , ThakerV , ChangAB . Vitamin K supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD008482.pub2]">Jagannath 2011</a>; <a href="./references#CD008482-bbs2-0052" title="JagannathVA , FedorowiczZ , ThakerV , ChangAB . Vitamin K supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008482.pub3]">Jagannath 2013</a>; <a href="./references#CD008482-bbs2-0053" title="JagannathVA , FedorowiczZ , ThakerV , ChangAB . Vitamin K supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews2015, Issue 1. [DOI: 10.1002/14651858.CD008482.pub4]">Jagannath 2015</a>; <a href="./references#CD008482-bbs2-0054" title="JagannathVA , ThakerV , ChangAB , PriceAI . Vitamin K supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews2017, Issue 8. [DOI: 10.1002/14651858.CD008482.pub5]">Jagannath 2017</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008482-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008482-sec-0014"></div> <p>To determine the effects of vitamin K supplementation on the morbidities in people with CF. </p> <p>To investigate the hypotheses that vitamin K will decrease deficiency‐related coagulopathy, increase BMD, decrease risk of fractures and improve quality of life (QoL) in people with CF. </p> <p>To determine the optimal dose and route of administration of vitamin K for people with CF (for both routine and therapeutic use). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008482-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008482-sec-0015"></div> <section id="CD008482-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008482-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) and quasi‐RCTs.</p> </section> <section id="CD008482-sec-0018"> <h4 class="title">Types of participants</h4> <p>Children and adults with a diagnosis of CF (defined by sweat test or genetic testing or both). </p> <p>Exclusion criteria: any intervention which may affect the interpretation of the effects of vitamin K or any allergy to vitamin K: </p> <p> <ul id="CD008482-list-0001"> <li> <p>any anticoagulation in the past three months (will make interpretation of vitamin K effects on blood coagulation difficult); </p> </li> <li> <p>bisphosphonates in the past six months (will make interpretation of vitamin K effects on bone metabolism difficult); </p> </li> <li> <p>allergy to vitamin K.</p> </li> </ul> </p> </section> <section id="CD008482-sec-0019"> <h4 class="title">Types of interventions</h4> <p>All preparations of vitamin K used as a supplement compared to placebo or no supplementation at any dose and for any duration. RCTs comparing different doses and regimens of vitamin K were also considered. </p> </section> <section id="CD008482-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD008482-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008482-list-0002"> <li> <p>Clinical outcomes related to coagulopathy (<a href="http://archie.cochrane.org/sections/documents/view?version=35357013530095106615100105131819&amp;format=REVMAN#REF-Sutor-1995" target="_blank">Sutor 1995</a>) </p> <ol id="CD008482-list-0003"> <li> <p>time to cessation of bleeding manifestations (symptomatic coagulopathy)  </p> </li> <li> <p>time to normalisation of sub‐therapeutic international normalized ratio (INR) (asymptomatic or sub‐clinical coagulopathy) </p> </li> </ol> </li> <li> <p>Bone formation outcome measures   </p> <ol id="CD008482-list-0004"> <li> <p>BMD at the spine (L1‐L4) and the total hip (measured by dual energy X‐ray absorptiometry (DEXA) scans with z score compared to reference population) (<a href="./references#CD008482-bbs2-0014" title="BorowitzD , BakerRD , StallingsV . Consensus report on nutrition for paediatric patients with cystic fibrosis. Journal of Pediatric Gastroenterology &amp; Nutrition2002;35:246-59.">Borowitz 2002</a>)     </p> </li> <li> <p>reduction in risk of bone fractures </p> </li> </ol> </li> <li> <p>QoL (e.g. the CFQ‐R (<a href="./references#CD008482-bbs2-0035" title="QuittnerAL , SweenyS , WatrousM , MunzenbergerP , BearssK , GibsonNA , et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. Journal of Pediatric Psychology2000;25(6):403-14.">Quittner 2000</a>) and the CFQoL (<a href="./references#CD008482-bbs2-0024" title="GeeL , AbbottJ , ConwaySP , EtheringtonC , WebbAK . Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax2000;55(11):946-54. [PMID: 11050265]">Gee 2000</a>)) </p> </li> </ol> </p> </section> <section id="CD008482-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008482-list-0005"> <li> <p>Nutritional parameters (including z scores or centiles)</p> <ol id="CD008482-list-0006"> <li> <p>weight</p> </li> <li> <p>height </p> </li> <li> <p>body mass index (BMI)</p> </li> </ol> </li> <li> <p>Adverse events</p> <ol id="CD008482-list-0007"> <li> <p>mild (not requiring intervention)</p> </li> <li> <p>moderate (requiring treatment)</p> </li> <li> <p>severe (life threatening or requiring hospitalisation)</p> </li> </ol> </li> <li> <p>Serum levels</p> <ol id="CD008482-list-0008"> <li> <p>% undercarboxylated osteocalcin (ucOC) level</p> </li> <li> <p>ucOC/cOC (carboxylated osteocalcin) ratio</p> </li> </ol> </li> <li> <p>Vitamin K‐specific laboratory outcomes</p> <ol id="CD008482-list-0009"> <li> <p>plasma level of vitamin K1 (measured by high performance liquid chromatography (HPLC) and fluorescence detection (<a href="./references#CD008482-bbs2-0049" title="WangLY , BatesCJ , YanL , HarringtonDJ , ShearerMJ , PrenticeA . Determination of phylloquinone (vitamin K1) in plasma and serum by HPLC with fluorescence detection. Clinica Chimica Acta2004;347(1-2):199-207. [PMID: 15313159]">Wang 2004</a>) </p> </li> <li> <p>PIVKA or antagonism factor II (PIVKA II) levels (measured by enzyme‐linked immunosorbent assay (ELISA)) (<a href="./references#CD008482-bbs2-0011" title="BelleM , HanssM , GuillaumontM , LeclercqM , GuinetR . Des-gamma-carboxyprothrombin detection by immunoblotting after polyacrylamide gelaffinoelectrophoresis in human plasmas. Electrophoresis1991;12(4):294-7. [PMID: 2070784]">Belle 1991</a>; <a href="./references#CD008482-bbs2-0012" title="BelleM , BrebantR , GuinetR , LeclercqM . Production of a new monoclonal antibody specific to human des-gamma-carboxyprothrombin in the presence of calcium ions. Application to the development of a sensitive ELISA-test. Journal of Immunoassay1995;16(2):213-29. [PMID: 7629279]">Belle 1995</a>) </p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD008482-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>There are no restrictions regarding language or publication status.</p> <section id="CD008482-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified relevant trials from the Group's Cystic Fibrosis Trials Register using the term: 'vitamin K'. </p> <p>A systematic search without language restrictions was conducted using the optimally sensitive strategy developed for the Cochrane Collaboration to identify all relevant published and unpublished randomised controlled trials (<a href="http://archie.cochrane.org/sections/documents/view?version=36145846209094572036100702122112&amp;format=REVMAN#REF-Lefebvre-2009" target="_blank">Lefebvre 2009</a>) in the Cystic Fibrosis Trials Register which is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Cystic Fibrosis and Genetic Disorders Group <a href="https://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of the latest search: 12 August 2019.</p> <p>We also searched online clinical trials registries (<a href="./appendices#CD008482-sec-0100">Appendix 1</a>). </p> </section> <section id="CD008482-sec-0025"> <h4 class="title">Searching other resources</h4> <p>The following additional resources were used:</p> <p> <ol id="CD008482-list-0010"> <li> <p>the bibliographical references of identified studies were searched for citations to additional studies; </p> </li> <li> <p>personal contact with corresponding authors of relevant trials or reviewers and other experts. </p> </li> </ol> </p> </section> </section> <section id="CD008482-sec-0026"> <h3 class="title" id="CD008482-sec-0026">Data collection and analysis</h3> <section id="CD008482-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Up to the 2017 update, two review authors (Vanitha Jagannath (VJ) and Zbys Fedorowicz (ZF)) independently assessed the abstracts of trials resulting from the searches. For 2020 update two review authors (VJ and Vidhu Thaker (VT)) independently assessed the abstracts for inclusion in the review. We obtained full text copies of all relevant and potentially relevant trials, those appearing to meet the inclusion criteria, and those for which there was insufficient detail in the title and abstract to make a clear decision. The two authors then independently assessed the full text papers. There were no disagreements; however, if there are any disagreements on the eligibility of trials in the future, we will resolve these through discussion and consensus, or through a third party Amy Price (AP). All irrelevant records were excluded and details of the trials and the reasons for their exclusion were noted in the tables (<a href="./references#CD008482-sec-0111" title="">Characteristics of excluded studies</a>) in RevMan (<a href="./references#CD008482-bbs2-0039" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> </section> <section id="CD008482-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We collected outcome data using a predetermined form designed for this purpose and entered details for the included trials into the tables in RevMan (<a href="./references#CD008482-sec-0110" title="">Characteristics of included studies</a>; <a href="./references#CD008482-bbs2-0039" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> <p>The authors extracted the following details.</p> <p> <ol id="CD008482-list-0011"> <li> <p>Trial methods</p> <ol id="CD008482-list-0012"> <li> <p>method of allocation</p> </li> <li> <p>masking of participants, investigators and outcome assessors</p> </li> <li> <p>exclusion of participants after randomisation and proportion and reasons for losses at follow‐up </p> </li> </ol> </li> <li> <p>Participants</p> <ol id="CD008482-list-0013"> <li> <p>country of origin and study setting</p> </li> <li> <p>sample size</p> </li> <li> <p>age</p> </li> <li> <p>gender</p> </li> <li> <p>inclusion and exclusion criteria</p> </li> </ol> </li> <li> <p>Intervention</p> <ol id="CD008482-list-0014"> <li> <p>type</p> </li> <li> <p>dose and frequency</p> </li> <li> <p>duration of intervention in follow‐up</p> </li> </ol> </li> <li> <p>Control</p> <ol id="CD008482-list-0015"> <li> <p>type</p> </li> <li> <p>dose and frequency</p> </li> <li> <p>duration of intervention in follow‐up</p> </li> </ol> </li> <li> <p>Outcomes: primary and secondary outcomes mentioned in the <a href="#CD008482-sec-0020">Types of outcome measures</a> section of this review and categorised and grouped accordingly: short‐term outcomes (less than 12 months) and medium‐ to long‐term outcomes (over 12 months) </p> </li> </ol> </p> <p>If stated in the trial reports, we recorded the sources of funding of any of the included trials. </p> <p>The review authors used this information to help them assess clinical heterogeneity and the external validity of any included trials. </p> <p>The review authors have presented the comparison of vitamin K versus control separately to the comparison of high‐dose versus low‐dose vitamin K. </p> </section> <section id="CD008482-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For the original review, two authors (VJ, ZF) independently graded the selected trials using a simple contingency form and followed the domain‐based evaluation described in chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008482-bbs2-0027" title="HigginsJP , AltmanDG . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). The authors compared evaluations and discussed and resolved any inconsistencies in these evaluations. </p> <p>The authors assessed the following domains as 'Yes' (i.e. low risk of bias), 'Unclear' (uncertain risk of bias) or 'No' (i.e. high risk of bias): </p> <p> <ol id="CD008482-list-0016"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (of participants, personnel and outcome assessors);</p> </li> <li> <p>incomplete outcome data addressed;</p> </li> <li> <p>free of selective outcome reporting;</p> </li> <li> <p>free of other bias.</p> </li> </ol> </p> <p>The authors categorised the risk of bias in any included RCTs according to the following:</p> <p> <ul id="CD008482-list-0017"> <li> <p>low risk of bias (plausible bias unlikely to seriously alter the results) if all criteria met; </p> </li> <li> <p>unclear risk of bias (plausible bias that raises some doubt about the results) if one or more criteria assessed as unclear; or  </p> </li> <li> <p>high risk of bias (plausible bias that seriously weakens confidence in the results) if one or more criteria not met. </p> </li> </ul> </p> <p>We report these assessments for each trial in the tables in the review (<a href="#CD008482-sec-0054">Risk of bias in included studies</a>). </p> </section> <section id="CD008482-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we planned to express results as odds ratios (OR) with 95% confidence intervals (CI). For continuous outcomes, we calculated the mean difference (MD); we would have calculated the standardized mean difference (SMD) if different measurement scales had been used. We planned to express any time‐to‐event outcomes data as ORs or hazards ratios. </p> </section> <section id="CD008482-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We included trials with a parallel group design, such that participants were randomised to either intervention or control with subsequent analysis at individual allocation level. Unit of analysis issues can arise with cross‐over trials and therefore we decided not to include end‐of‐trial data from these trials because the effects of vitamin K on bone metabolism are likely to be long‐term and an appropriate wash‐out period cannot be defined. However, we planned to include any data reported from the first intervention period. </p> </section> <section id="CD008482-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact the authors of any trials where we needed clarification of trial design or results (at all stages of the review and updates). We have only received a response from the investigators of one of the trials which reported some data for two of our secondary outcomes, but presented these as graph plots from which we were unable to obtain precise data (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). After successful contact with the principal investigator via electronic mail we received the relevant individual patient data for these two outcomes and have presented them in this review. </p> </section> <section id="CD008482-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>As we were only able to include three trials in this review and have not been able to combine data in a meta‐analysis, we did not assess heterogeneity; but in future updates of this review, if we are able to include further trials, we will apply the following methods of assessment. </p> <p>We will assess clinical diversity between the trials by examining the trial characteristics, the similarity between the types of participants, the interventions and the outcomes as specified in the inclusion criteria. </p> <p>We will assess statistical heterogeneity using a Chi² test and the I² statistic, where I² values of 30% to 60% indicate moderate to high, 50% to 90% substantial and 75% to 100% considerable heterogeneity. We will consider heterogeneity to be significant when the P value is less than 0.10 (<a href="./references#CD008482-bbs2-0026" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). </p> </section> <section id="CD008482-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>The paucity of trials included in this review did not permit an assessment of publication bias. If we had identified a sufficient number of trials for inclusion in this review (at least 10), we would have assessed publication bias according to the recommendations on testing for funnel plot asymmetry as described in chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008482-bbs2-0045" title="SterneJA , EggerM , MoherD , on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Sterne 2011</a>). If we had then identified asymmetry, we would have tried to assess other possible causes and explored these further in the Discussion section of the review, if appropriate. </p> </section> <section id="CD008482-sec-0035"> <h4 class="title">Data synthesis</h4> <p>For the original review, two review authors (VJ and ZF) analysed the data in Review Manager (<a href="./references#CD008482-bbs2-0039" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) and reported them as specified in chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008482-bbs2-0019" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org . [REFWORKS: ID: 1335]">Deeks 2011</a>). </p> <p>Although we included three RCTs in this review, we were only able to report reliable data from one of them (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>) and therefore did not carry out a meta‐analysis. If, at a later date we include further trials in this review, we will apply the following methods of data synthesis. When we include sufficient numbers of trials investigating similar interventions, we will conduct the analysis in RevMan (<a href="./references#CD008482-bbs2-0039" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). In general, we will use the fixed‐effect model; but if there is substantial clinical diversity, we will use the random‐effects model with trials grouped by action. </p> </section> <section id="CD008482-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Lack of data did not permit a subgroup analysis, but in future updates and if further data become available we plan to carry out the following subgroup analyses: </p> <p> <ol id="CD008482-list-0018"> <li> <p>cumulative dose (as per kg body weight per day) of vitamin K2;</p> </li> <li> <p>route of administration (oral or parenteral);</p> </li> <li> <p>baseline plasma level of vitamin K1 (subnormal versus normal);</p> </li> <li> <p>presence or absence of any of the following: pancreatic insufficiency, liver dysfunction, bowel resection or prolonged usage of antibiotics and chronic steroid administration; </p> </li> <li> <p>mean 25OH vitamin D level.</p> </li> </ol> </p> </section> <section id="CD008482-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>In view of the low number of trials included in this review, a sensitivity analysis was not possible. For future updates and if we are able to include sufficient trials, we will undertake sensitivity analyses to assess the robustness of our review results by repeating the analysis with the following adjustments: </p> <p> <ul id="CD008482-list-0019"> <li> <p>exclusion of trials with unclear or inadequate allocation concealment;</p> </li> <li> <p>exclusion of trials with unclear or inadequate blinding of outcomes assessment;</p> </li> <li> <p>exclusion of trials with unclear or inadequate completeness of follow‐up;</p> </li> <li> <p>exclusion of quasi‐randomised trials.</p> </li> </ul> </p> </section> <section id="CD008482-sec-0038"> <h4 class="title">Summary of findings</h4> <p>We have prepared a summary of findings table according to GRADEpro guidelines to summarise the effect of supplementation of vitamin K compared with placebo in people with CF (<a href="./references#CD008482-bbs2-0040" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al, on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017a</a>; <a href="./references#CD008482-bbs2-0041" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al, on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017b</a>). We have included the outcomes of time to cessation of bleeding, BMD (lumbar spine z score), QoL measured using both CFQ‐R and CFQOL, adverse events and the laboratory parameters of PIVKA and undercarboxylated osteocalcin (<a href="./full#CD008482-tbl-0001">summary of findings Table 1</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008482-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008482-sec-0039"></div> <section id="CD008482-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD008482-sec-0041"> <h4 class="title">Results of the search</h4> <p>The electronic searches retrieved references to 10 trials. After examination of the titles and abstracts of these references, we planned to eliminate trials that did not match our inclusion criteria and were clearly ineligible. This was not the case and we obtained full text copies of the potentially eligible trials, which we subjected to further evaluation. The review authors discussed the eligibility of these trials, resolved any remaining uncertainties by consensus. We included three trials (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>), excluded five trials (<a href="./references#CD008482-bbs2-0004" title="CornelissenEA , vanLieburgAF , MotoharaK , vanOostromCG . Vitamin K status in cystic fibrosis. Acta Paediatrica1992;81(9):658-61. [PMID: 1421902]">Cornelissen 1992</a>; <a href="./references#CD008482-bbs2-0005" title="GreyV , AtkinsonS , DruryD , CaseyL , FerlandG , GundbergC , et al. Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. Pediatrics2008;122(5):1014-20. [PMID: 18977981]">Grey 2008</a>; <a href="./references#CD008482-bbs2-0006" title="MoslerK , vonKriesR , VermeerC , SaupeJ , SchmitzT , SchusterA . Assessment of vitamin K deficiency in CF--how much sophistication is useful?Journal of Cystic Fibrosis2003;2(2):91-6. [PMID: 15463856]">Mosler 2003</a>; <a href="./references#CD008482-bbs2-0007" title="NicolaidouP , StavrinadisI , LoukouI , PapadopoulouA , GeorgouliH , DourosK , et al. The effect of vitamin K supplementation on biochemical markers of bone formation in children and adolescents with cystic fibrosis. European Journal of Pediatrics2006;165(8):540-5. [PMID: 16622660]">Nicolaidou 2006</a>; <a href="./references#CD008482-bbs2-0008" title="WilsonDC , RashidM , DuriePR , TsangA , KalninsD , AndrewM , et al. Treatment of vitamin K deficiency in cystic fibrosis: Effectiveness of a daily fat-soluble vitamin combination. Journal of Pediatrics2001;138(6):851-5. [PMID: 11391328]">Wilson 2001</a>), and have listed two trials as awaiting classification until we obtain further information from the trialists (<a href="./references#CD008482-bbs2-0009" title="vanHoornJH , HendriksJJ , VermeerC , ForgetPP . Vitamin K supplementation in cystic fibrosis. Archives of Disease in Childhood2003;88(11):974-5. [CFGD REGISTER: GN104] [PMID: 14612359]">van Hoorn 2003</a>; <a href="./references#CD008482-bbs2-0010" title="vanHoornJH , SchurgersJJ , VermeerC , EscherHC , HendriksHJ . The effect of vitamin K supplementation on bone status in children with cystic fibrosis. Pediatric Pulmonology2008;43(S31):421. [CFGD REGISTER: GN130] ">van Hoorn 2008</a>). </p> </section> <section id="CD008482-sec-0042"> <h4 class="title">Included studies</h4> <p>Three trials are included in the review; two of these did not address any of our primary outcomes and only reported on two of the secondary outcomes, while one trial reported on a primary outcome (BMD). Albeit the trials were assessed as having a moderate risk of bias, and provided limited data, it was considered that their inclusion and the reporting of their results would provide at least some evidence towards answering this research question. </p> <section id="CD008482-sec-0043"> <h5 class="title">Vitamin K versus control</h5> <section id="CD008482-sec-0044"> <h6 class="title">Characteristics of the trial</h6> <p>Two trials compared vitamin K to control; one was of parallel design (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). One of the trials was cross‐over in design, but did not include a washout period and thus the potential risk of bias as a consequence of the carry‐over of treatment effect could not be ruled out (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). Although trials with a cross‐over design were eligible for inclusion in this review, we had specified that only data from the first intervention period would be used. Unfortunately, the trial investigators only provided an analysis across both treatment periods and, even though we were unable to contact the authors to obtain the first‐period data, this trial has been included in the review but it has not been possible to enter the data into a meta‐analysis. </p> <p>Both were single‐centre trials; one was carried out at the CF Clinic of the Children's National Medical Center (CNMC), Washington DC, USA (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>) and one was conducted at CF clinics of Barts and the London, Kings College Hospital and Lewisham University NHS Trusts (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> <p>The duration of two trials differed. In the cross‐over trial, the participants were allocated to either active intervention or no‐treatment control for a four‐week period and then crossed over for a further four weeks, but without undergoing a washout period (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). In the parallel trial the treatment period was 12 months (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> <p>The providers of care in both trials were hospital staff and the assessors of outcomes were the investigators and other healthcare providers (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> </section> <section id="CD008482-sec-0045"> <h5 class="title">Characteristics of the participants</h5> <p>The total sample size comprised of 56 participants between the ages of 8 and 46 years (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> <p>All of the participants in the Beker trial were pancreatic insufficient, as documented by previous fecal fat measurement, and they received replacement therapy of 750 to 200 units of lipase/kg of body weight at meal times during the course of the trial (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). Participants with liver disease (diagnosed by ultrasound, liver function tests or hepatomegaly or both) and those who were taking supplemental therapeutic vitamin K to treat coagulopathies at enrolment were excluded from this trial (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). Unfortunately, such details are not currently available from the remaining trial (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> <section id="CD008482-sec-0046"> <h5 class="title">Characteristics of the interventions</h5> <p>The active intervention in the Beker trial consisted of 5 mg oral vitamin K1 supplementation per week and the control was no supplementation for four weeks; participants then crossed over for a second four‐week period (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). Compliance with the intervention by participants was verified by the trial coordinator at each visit. Oral antibiotic medications of cephalosporin; sulfamethoxazole; erythromycin as well as concomitant usage of bronchodilators and standard multivitamins and 200 to 400 IU vitamin E were allowed during the course of the trial. </p> <p>The second trial randomised participants to either 10 mg/day vitamin K or placebo (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> <section id="CD008482-sec-0047"> <h5 class="title">Characteristics of the outcome measures</h5> <p>One trial reported on one primary outcome BMD (z scores of femur, hip and lumbar spine) and also a secondary outcome of osteocalcin levels; however, since there is only an abstract available we do not have complete information (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> <p>None of the primary outcomes specified in the protocol for the review were considered in the second trial (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). This cross‐over trial did, however, assess plasma vitamin K1 levels and serum undercarboxylated osteocalcin levels at the end of each period (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). Dietary intake records to estimate the extent of dietary contribution of vitamin K1 were also maintained by the participants; the vitamin K1 data of foods were analysed using Nutritionist III software, the database, however, did not have complete vitamin K1 data for many foods (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). </p> </section> <section id="CD008482-sec-0048"> <h5 class="title">High‐dose vitamin K versus low‐dose vitamin K</h5> <section id="CD008482-sec-0049"> <h6 class="title">Characteristics of the trial</h6> <p>One parallel dose‐ranging trial lasting one month compared different doses of vitamin K (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). It was a single‐centre trial conducted at the Montreal Children's Hospital CF Clinic in Canada. The providers of care were hospital staff and the assessors of outcomes were the investigators and other healthcare providers (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). </p> </section> </section> <section id="CD008482-sec-0050"> <h5 class="title">Characteristics of the participants</h5> <p>The total sample size comprised 14 participants. The investigators reported that only pancreatic insufficient participants were included, but provided no further details; participants with liver disease (diagnosed by ultrasound, liver function tests or hepatomegaly or both) and those who were taking supplemental therapeutic vitamin K to treat coagulopathies at enrolment were excluded (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). </p> </section> <section id="CD008482-sec-0051"> <h5 class="title">Characteristics of the interventions</h5> <p>The participants in the Drury trial were randomised to either the orally administered injectable formulation of vitamin K1 phytonadione of 1 mg/day (diluted to 1 mg/mL) or the 5 mg/day dose (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). </p> </section> <section id="CD008482-sec-0052"> <h5 class="title">Characteristics of the outcome measures</h5> <p>This RCT did not report any of the primary outcomes specified in the protocol for the review. It did, however, report some data for two of our secondary outcomes, but these were presented as graph plots from which we were unable to obtain precise data (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). These assessments were of plasma vitamin K1 levels and serum undercarboxylated osteocalcin levels measured at the completion of the trial (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). </p> </section> </section> <section id="CD008482-sec-0053"> <h4 class="title">Excluded studies</h4> <p>Five trials were excluded from the review since these were not RCTs. Further information about the reasons for exclusion of trials is available in the tables (<a href="./references#CD008482-sec-0111" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD008482-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>All included trials were judged as having an 'unclear' risk of bias overall (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). These assessments were to a certain extent based on the inadequate reporting of several of the criteria that are considered to be important in the evaluation of methodological rigour in terms of trial design and conduct. For further details see the risk of bias tables in <a href="./references#CD008482-sec-0110" title="">Characteristics of included studies</a>, the risk of bias graph (<a href="#CD008482-fig-0001">Figure 1</a>) and the risk of bias summary (<a href="#CD008482-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD008482-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008482-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_n/nCD008482-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008482-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008482-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_n/nCD008482-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008482-sec-0055"> <h4 class="title">Allocation</h4> <p>The methods used to generate the allocation sequence were not reported in any trial. Moreover, none of the trials described how the allocation sequence was concealed, which did not allow us to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment. Inadequate reporting quality did not permit a clear judgement to be made for both domains in any of the included trials (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> <section id="CD008482-sec-0056"> <h4 class="title">Blinding</h4> <p>The measures used to blind trial participants and personnel from knowledge of which intervention a participant received or any information relating to whether the intended blinding was effective were not reported in any trial (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). However, whilst it may be accepted that blinding of participants and investigators in the Beker trial may not have been feasible, it was unclear if the assessors of the outcomes were adequately blinded (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). Therefore the judgement given for this domain in all trials was 'unclear'. </p> </section> <section id="CD008482-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>There were no withdrawals and no missing or incomplete data in the Beker trial (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>); and the only missing data in the Drury trial was as a result of the inability of the investigators to make the final outcome assessment for one participant (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). Therefore, we judge there to be a low risk of bias from incomplete outcome data in both of these trials. The judgement for the remaining trial was unclear in view of limited information obtained in the abstract (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> <section id="CD008482-sec-0058"> <h4 class="title">Selective reporting</h4> <p>Although trial protocols were not available for two trials, based on information presented in the methods sections of each of the reports, the investigators appear to have reported on all of their stated objectives and expected outcomes, a number of which were pre‐specified inclusion criteria for this systematic review (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). We therefore judge there to be a low risk of bias from selective reporting for these trials. For the remaining trial we judged the risk of bias to be unclear since although the protocol was available on trials registries, there was limited information reported in the abstract (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> <section id="CD008482-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>Insufficient information was provided in the reports to assess whether any other important risk of bias exists, and therefore the judgement for this domain in both trials was 'unclear' (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> </section> <section id="CD008482-sec-0060"> <h3 class="title" id="CD008482-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD008482-tbl-0001"><b>Summary of findings 1</b> Vitamin K compared to control for people with cystic fibrosis</a>; <a href="./full#CD008482-tbl-0002"><b>Summary of findings 2</b> Comparison of different vitamin K doses for people with cystic fibrosis</a> </p> <p>In the summary of findings table, the quality of the evidence has been graded for pre‐defined outcomes (see above) and definitions of these gradings are provided within the table (<a href="./full#CD008482-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD008482-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD008482-sec-0061"> <h4 class="title">Vitamin K versus control</h4> <p>Two trials (n = 56) reported on this comparison (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> <section id="CD008482-sec-0062"> <h5 class="title">Primary outcomes</h5> <section id="CD008482-sec-0063"> <h6 class="title">1. Clinical outcomes related to coagulopathy</h6> <p>Neither trial reported on this outcome (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> <section id="CD008482-sec-0064"> <h6 class="title">2. Bone formation outcome measures</h6> <p>One trial reported on bone formation outcome measures (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). The data on number of participants in each group could not be obtained from the abstract and hence we report the relevant details here narratively. We graded the quality of the evidence as very low. </p> <p>At baseline, 20% in the placebo group and 16.7% in the treatment group had femoral hip z scores less than ‐1.0 and 30% in the placebo group and 33.3% in the treatment group had lumbar spine z scores less than ‐1.0. One participant had a z score consistent with osteoporosis at the lumbar spine. </p> <p>At 12 months the mean (SD) change in the placebo group at the femoral hip z score was 0.053 (0.19) g/cm³ and in the treatment group was ‐0.20 (0.31) g/cm³. At the same time point, the mean (SD) change in the placebo group in z score at the lumbar spine was 0.041 (0.15) g/cm³ and in the treatment group it was ‐0.073 (0.30) g/cm³ (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> <section id="CD008482-sec-0065"> <h6 class="title">3. QoL</h6> <p>Neither trial reported on this outcome (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> </section> <section id="CD008482-sec-0066"> <h5 class="title">Secondary outcomes</h5> <section id="CD008482-sec-0067"> <h6 class="title">1. Nutritional parameters</h6> <p>Neither trial reported on this outcome (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> <section id="CD008482-sec-0068"> <h6 class="title">2. Adverse events</h6> <p>Neither trial reported on this outcome (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> <section id="CD008482-sec-0069"> <h6 class="title">3. Serum levels</h6> <p>In the Beker trial, the data for this outcome were analysed across both treatment periods and therefore we only report the end‐of‐trial data narratively (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). We advise caution in its interpretation and in any comparison with data from the other trials included in this review. </p> <section id="CD008482-sec-0070"> <p><b>a. % ucOC level</b></p> <p>In the Beker trial, all of the participants had increased serum ucOC concentrations at enrolment and prior to supplementation (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). It was reported that following supplementation and by the end of the trial the majority had successfully achieved the normal reference mean levels of ucOC (21%) (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). </p> <p>The second trial reported that supplementation with vitamin K improved carboxylation of osteocalcin (P = 0.007), but we do not have data for analysis (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> <section id="CD008482-sec-0071"> <p><b>b. ucOC/cOC ratio</b></p> <p>One trial reported the mean (SD) reduction in ucOC to cOC of 14.02% (15.94) in the treatment group compared to 3.69% (20.59) in the placebo group (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </section> </section> <section id="CD008482-sec-0072"> <h6 class="title">4. Vitamin K‐specific laboratory outcomes</h6> <section id="CD008482-sec-0073"> <p><b>a. Plasma level of vitamin K1</b></p> <p>In the Beker trial, a substantial number of the participants had below normal serum vitamin K levels at trial entry (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). Although the mean concentration of plasma vitamin K was higher in the supplemented group, in only less than half of the total number of participants were these levels reportedly brought into the normal range after supplementation with the 5 mg dose (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). </p> </section> <section id="CD008482-sec-0074"> <p><b>b. PIVKA or antagonism factor II levels</b></p> <p>In the Beker trial PIVKA‐II concentrations were elevated prior to supplementation and almost one third of the participants had PIVKA‐II levels within the normal range (≤ 2 ng/mL) following supplementation (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>) (very low‐quality evidence). </p> </section> </section> </section> </section> <section id="CD008482-sec-0075"> <h4 class="title">High‐dose vitamin K versus low‐dose vitamin K</h4> <p>Only one trial (n = 14) reported on this comparison (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). </p> <section id="CD008482-sec-0076"> <h5 class="title">Primary outcomes</h5> <p>The included trial did not report on any of the primary outcomes specified in the protocol for this review (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). </p> </section> <section id="CD008482-sec-0077"> <h5 class="title">Secondary outcomes</h5> <section id="CD008482-sec-0078"> <h6 class="title">1. Nutritional parameters</h6> <p>These were not assessed in the included trial (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). </p> </section> <section id="CD008482-sec-0079"> <h6 class="title">2. Adverse events</h6> <p>No adverse events were reported in the included trial (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). </p> </section> <section id="CD008482-sec-0080"> <h6 class="title">3. Serum levels</h6> <p>The Drury trial was underpowered (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). Despite obtaining individual patient data, the small number of participants and the degree of baseline imbalance in vitamin K and undercarboxylated osteocalcin levels (both within and between the groups) did not support analysis of the magnitude of individual response to treatment or control, i.e. the measure of change from baseline. Although it is likely that baseline imbalance may reflect the clinical variability of CF, the report did not provide sufficient clinical detail of the participants to enable any assessment of the degree of variability in presentation of CF. Therefore, the data for both of these outcomes have been presented in the analysis as the end of trial mean response for the total number of participants in each of the treatment and control groups. We also report the baseline means and SDs alongside the end of trial values in the additional tables (<a href="#CD008482-tbl-0003">Table 1</a>; <a href="#CD008482-tbl-0004">Table 2</a>). </p> <div class="table" id="CD008482-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Serum undercarboxylated osteocalcin (ucOC) percentage (Drury 2008)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>UcOC %<br/>Baseline mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>UcOC %<br/>End of study mean (SD)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (14.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (8.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.6 (9.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.2 (13.09)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>SD: standard deviation<br/>ucOC: undercarboxylated osteocalcin </p> </div> </div> <div class="table" id="CD008482-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Serum vitamin K levels (Drury 2008)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Serum vitamin K levels (nmol/L)<br/>Baseline mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Serum vitamin K levels (nmol/L)<br/>End of study mean (SD)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.52 (2.61)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15 (0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.98 (9.95)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>SD: standard deviation</p> </div> </div> <section id="CD008482-sec-0081"> <p><b>a. % ucOC level</b></p> <p>In the Drury trial, all of the participants had elevated % ucOC levels before supplementation (in excess of 21%), but these levels were reduced after one month of vitamin K1 supplementation (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). The overall level of % ucOC decreased from a median of 46.8% to 29.1%; and % ucOC levels decreased and returned to within the normal range in three out of the 13 participants by the end of the trial (one in the 5 mg/day group, two in the 1 mg/day group). The mean end of trial difference in % ucOC between the two intervention groups was MD ‐2.20 (95% CI ‐14.33 to 9.93) (<a href="./references#CD008482-fig-0003" title="">Analysis 1.1</a>) (very low‐quality evidence). </p> <p>There was no evidence of any difference between the 5 mg/day and the 1 mg/day vitamin K dosage in terms of statistically significant effect on ucOC levels at the end of the one‐month trial period (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). </p> </section> <section id="CD008482-sec-0082"> <p><b>b. ucOC/cOC (carboxylated osteocalcin) ratio (UCR)</b></p> <p>This outcome was not assessed in the included trial (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). </p> </section> </section> <section id="CD008482-sec-0083"> <h6 class="title">4. Vitamin K‐specific laboratory outcomes</h6> <section id="CD008482-sec-0084"> <p><b>a. Plasma level of vitamin K1</b></p> <p>In the Drury trial, the baseline vitamin K levels in seven out of the 14 participants were sub‐optimal (defined as less than 0.3 nmol/L) (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). The paper reported that serum vitamin K levels appeared to improve significantly (P &lt; 0.001) with supplementation, rising into the normal range in all of the participants who were below the optimum level. There was no statistically significant difference in effect between the 5 mg/day and the 1 mg/day vitamin K dose, ‐4.96 (95% CI ‐12.65 to 3.73) (<a href="./references#CD008482-fig-0004" title="">Analysis 1.2</a>). </p> </section> <section id="CD008482-sec-0085"> <p><b>b. PIVKA or antagonism factor II levels</b></p> <p>This outcome was not assessed in the included trial (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008482-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008482-sec-0086"></div> <section id="CD008482-sec-0087"> <h3 class="title" id="CD008482-sec-0087">Summary of main results</h3> <p>There are three trials included in this review; two of these (n = 56) compare vitamin K to control (placebo or no supplementation) and one (n = 14) compares different doses of vitamin K. The results from the included trials could not be pooled and entered into a meta‐analysis. </p> <section id="CD008482-sec-0088"> <h4 class="title">Vitamin K versus control</h4> <p>Only one trial (n = 38) reported on any of our primary outcomes and found no changes in BMD after 12 months of vitamin K supplementation in one trial (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). Neither trial reported on nutritional parameters or adverse events, however, the trials reported an increase in serum vitamin K levels, and a decrease in the ucOC levels which returned to normal following supplementation with oral vitamin K (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). The PIVKA levels also showed a decrease and a return to normal in the Beker trial following supplementation (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>). </p> </section> <section id="CD008482-sec-0089"> <h4 class="title">High‐dose vitamin K versus low‐dose vitamin K</h4> <p>The only trial (n = 14) comparing different doses of vitamin K (1 mg/day versus 5 mg/day) did not report on any of our primary outcomes, or the secondary outcomes of nutritional parameters and adverse events (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). The trial did report that there did not appear to be any significant difference in serum ucOC or vitamin K levels, but the quality of the evidence was very low (<a href="./references#CD008482-bbs2-0002" title="DruryD , GreyVL , FerlandG , GundbergC , LandsLC . Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. Journal of Cystic Fibrosis2008;7(5):457-9. [CFGD REGISTER: GN131] [PMID: 18511355]">Drury 2008</a>). While the trial reported that serum vitamin K levels improved with supplementation, there was no difference between the high‐dose and low‐dose groups. </p> </section> </section> <section id="CD008482-sec-0090"> <h3 class="title" id="CD008482-sec-0090">Overall completeness and applicability of evidence</h3> <p>The noticeable absence in the included trials of any assessments of important clinical outcomes related to coagulopathy or growth and improvement in QoL as a result of vitamin K supplementation does somewhat limit the overall completeness and ultimately the generalisability of the evidence to the wider CF population. Equally, the short duration and follow‐up of two included trials and the limited data from the longest (12‐month trial) does not permit any conclusions to be made about the longer‐term benefits and any potential harms of vitamin K supplementation. </p> <p>Future research should aim to close this gap in the evidence by focusing more closely on some of the patient‐relevant and preferred outcomes rather than solely on biochemical laboratory analyses. </p> </section> <section id="CD008482-sec-0091"> <h3 class="title" id="CD008482-sec-0091">Quality of the evidence</h3> <p>Some of the practical and methodological difficulties faced by investigators of this research question were highlighted in these trials and the quality of the evidence across all outcomes assessed was very low (<a href="./full#CD008482-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD008482-tbl-0002">summary of findings Table 2</a>). The key factors which are likely to have had a degree of impact on the quality level of the evidence for the outcomes assessed in this review can be linked to the design and implementation of the included trials, and in particular to the concealment of the allocation sequence and blinding of investigators and outcome assessors. The trials included in this review were underpowered and of short duration (the longest being 12 months) which was illustrated by the wide CIs in the comparisons of treatment effect and reflected the degree of imprecision in these. In addition there were issues due to different scales of measurement for the outcomes and unavailable complete data. </p> </section> <section id="CD008482-sec-0092"> <h3 class="title" id="CD008482-sec-0092">Potential biases in the review process</h3> <p>Although it would be not unreasonable to assume that the comprehensive electronic searches employed in this review will have identified all existing RCTs and thereby helped to limit bias in the conduct of this review, the absence of any other published RCTs over the intervening 13 years between the earliest and latest of the included trials and their scant contribution to the outcomes specified for this review, might presuppose an indication of publication bias. </p> </section> <section id="CD008482-sec-0093"> <h3 class="title" id="CD008482-sec-0093">Agreements and disagreements with other studies or reviews</h3> <p>Several trials have indicated a degree of support for the need for supplementation in addition to emphasising the comparative safety of oral supplementation with vitamin K in people with CF (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0014" title="BorowitzD , BakerRD , StallingsV . Consensus report on nutrition for paediatric patients with cystic fibrosis. Journal of Pediatric Gastroenterology &amp; Nutrition2002;35:246-59.">Borowitz 2002</a>; <a href="./references#CD008482-bbs2-0036" title="RamseyBW , FarrellPM , PencharzP , and the Consensus Committee. Nutritional assessment and management in cystic fibrosis: a consensus report. American Journal of Clinical Nutrition1992;55(1):108-16.">Ramsey 1992</a>; <a href="./references#CD008482-bbs2-0043" title="SinaasappelM , SternM , LittlewoodJ , WolfeS , SteinkampG , HeijermanHG , et al. Nutrition in patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis2002;1(2):51-75. [PMID: 15463811]">Sinaasappel 2002</a>); but there is no agreement amongst the trials about the most appropriate dosage. However, there is some concern that the adequacy of dosing based on the measurement of vitamin K levels may be inaccurate and that PIVKA levels and ucOC levels may be better indicators of effectiveness of supplementation. Some trials suggest a complimentary role for quantified dietary intake of vitamin K in people with CF (<a href="./references#CD008482-bbs2-0021" title="DoughertyKA , SchallJI , StallingsVA . Suboptimal vitamin K status despite supplementation in children and young adults with cystic fibrosis. American Journal of Clinical Nutrition2010;92(3):660-7. [PMID: 20554788]">Dougherty 2010</a>). This review did not show anything conclusively to agree or disagree with these trials. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008482-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/urn:x-wiley:14651858:media:CD008482:CD008482-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008482-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_n/nCD008482-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_t/tCD008482-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_n/nCD008482-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008482-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/urn:x-wiley:14651858:media:CD008482:CD008482-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008482-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_n/nCD008482-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_t/tCD008482-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_n/nCD008482-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008482-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/urn:x-wiley:14651858:media:CD008482:CD008482-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 1 mg versus 5 mg oral vitamin k, Outcome 1: Serum % uncarboxylated osteocalcin" data-id="CD008482-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_n/nCD008482-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_t/tCD008482-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: 1 mg versus 5 mg oral vitamin k, Outcome 1: Serum % uncarboxylated osteocalcin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/references#CD008482-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_n/nCD008482-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008482-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/urn:x-wiley:14651858:media:CD008482:CD008482-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 1 mg versus 5 mg oral vitamin k, Outcome 2: Serum vitamin k levels" data-id="CD008482-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_n/nCD008482-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_t/tCD008482-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: 1 mg versus 5 mg oral vitamin k, Outcome 2: Serum vitamin k levels</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/references#CD008482-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/media/CDSR/CD008482/image_n/nCD008482-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008482-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vitamin K compared to control for people with cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vitamin K compared to control for people with cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with cystic fibrosis<br/><b>Setting</b> : community or health care facilities<br/><b>Intervention</b> : vitamin K<br/><b>Comparison</b>: placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Vitamin K</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to cessation of bleeding</b> </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bone mineral density</b>: lumbar spine z score </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The mean (SD) change in the placebo group in z score at the lumbar spine was 0.041 (0.15) g/cm³ and in the treatment group it was ‐0.073 (0.30) g/cm³. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> <p>⊕⊝⊝⊝<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors also reported mean change in z score in those participants 25 or under and those that were over 25 years. They concluded that vitamin K had no significant effect except in participants that were over 25 years. where vitamin K may have a protective effect against decline in BMD (<a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> <p>The mean (SD) change in the placebo group at the femoral hip z score was 0.053 (0.19) g/cm³ and in the treatment group was ‐0.20 (0.31) g/cm³. The mean change in femoral hip z score ≤ 25, but there is not enough information to comment on the statistical significance of this. </p> <p>The authors report no significant effect of vitamin K on bone mineral density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b>: CFQ‐R </p> <p><b>Follow‐up</b>:12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b>: CFQoL </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PIVKA II levels</b>: change in PIVKA II (ng/mL) </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Mean (SD) PIVKA‐II concentrations increased significantly when participants were not supplemented (5.1 (3.2) ng/mL in the supplemented group and 21.8 (3.2) ng/mL in the unsupplemented group) and almost one third (5 out of 18) of the participants had PIVKA‐II levels within the normal range (≤ 2 ng/mL) following supplementation. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> <p>⊕⊝⊝⊝<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Uncarboxylated osteocalcin</b>: </p> <p>change in carboxylation of osteocalcin (% Glu‐OC)</p> <p><b>Follow‐up</b>: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies (total n = 56) narratively reported that vitamin K improved carboxylation of osteocalcin (<a href="./references#CD008482-bbs2-0001" title="BekerLT , AhrensRA , FinkRJ , O'BrienME , DavidsonKW , SokollLJ , et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition1997;24(5):512-7. [CFGD REGISTER: GN61b] [PMID: 9161943]BekerLT , AhrensRA , FinkRJ , SadowskiJA , DavidsonKW , SokollLJ , et al. Abnormal Vitamin K status in cystic fibrosis patients. Pediatric Pulmonology1994;18 Suppl 10:358. [CFGD REGISTER: GN61a] ">Beker 1997</a>; <a href="./references#CD008482-bbs2-0003" title="EUCTR2006-000945-20-GB. To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000945-20-GB (first received 18 September 2006). [CENTRAL: CN-01814462] [CFGD REGISTER: CO47b] ISRCTN14200211. Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14200211 (first received 09 May 2008). [CENTRAL: CN-01816363] [CFGD REGISTER: CO47c] PowellM , KuitertL . Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis. Pediatric Pulmonology2010;45(S33):421. [ABSTRACT NO: 556] [CFGD REGISTER: CO47] ">Kuitert 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI</b> : confidence interval; <b>CFQoL</b> : Cystic Fibrosis Quality of Life; <b>CFQ‐R</b> : Cystic Fibrosis Questionnaire ‐ Revised; <b>PIVKA‐II</b> : proteins induced by vitamin K absence; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty</b> : our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate.The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice due to an unclear risk of bias in one RCT, particularly for the domains of randomisation, allocation concealment and blinding. </p> <p><sup>b</sup> Downgraded once due to imprecision as numbers were too low to meet the optimal information size. </p> <p><sup>c</sup> Downgraded twice due to risk of bias within one RCT. The randomisation and allocation concealment processes were unclear and it wasn't possible to blind either participants or healthcare providers. It was unclear whether the outcome assessors were blinded. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vitamin K compared to control for people with cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008482-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Comparison of different vitamin K doses for people with cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High‐dose vitamin K compared to low‐dose vitamin K for people with cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with cystic fibrosis<br/><b>Setting</b> : community or health care facilities<br/><b>Intervention</b> : high‐dose vitamin K<br/><b>Comparison</b>: low‐dose vitamin K </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with low‐dose vitamin K</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with high‐dose vitamin K</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to cessation of bleeding</b> </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bone mineral density</b>: lumbar spine z score </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b>: CFQ‐R </p> <p><b>Follow‐up</b>:12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b>: CFQoL </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PIVKA II levels</b>: change in PIVKA II (ng/mL) </p> <p><b>Follow‐up</b>: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Uncarboxylated osteocalcin</b>: </p> <p>change in carboxylation of osteocalcin level (% Glu‐OC)</p> <p><b>Follow‐up</b>: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Uncarboxylated osteocalcin was 2.20% lower in the 1 mg group than in the 5 mg group (14.33% lower to 9.93% higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> <p>⊕⊝⊝⊝<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI</b> : confidence interval; <b>CFQoL</b> : Cystic Fibrosis Quality of Life; <b>CFQ‐R</b> : Cystic Fibrosis Questionnaire ‐ Revised; <b>PIVKA‐II</b> : proteins induced by vitamin K absence; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty</b> : our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate.The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once due to imprecision as numbers were too low to meet the optimal information size. </p> <p><sup>b</sup> Downgraded twice due to risk of bias within the single RCT. There was an unclear risk of bias across four of the six domains, particularly around randomisation, allocation conclealment and blinding. This was a cross‐over trial with no wash‐out period and there was therefore a potential carry‐over of treatment effect. No first‐period data were available. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Comparison of different vitamin K doses for people with cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008482-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Serum undercarboxylated osteocalcin (ucOC) percentage (Drury 2008)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>UcOC %<br/>Baseline mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>UcOC %<br/>End of study mean (SD)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (14.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (8.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.6 (9.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.2 (13.09)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>SD: standard deviation<br/>ucOC: undercarboxylated osteocalcin </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Serum undercarboxylated osteocalcin (ucOC) percentage (Drury 2008)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008482-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Serum vitamin K levels (Drury 2008)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Serum vitamin K levels (nmol/L)<br/>Baseline mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Serum vitamin K levels (nmol/L)<br/>End of study mean (SD)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.52 (2.61)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15 (0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.98 (9.95)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>SD: standard deviation</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Serum vitamin K levels (Drury 2008)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/full#CD008482-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008482-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">1 mg versus 5 mg oral vitamin k</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Serum % uncarboxylated osteocalcin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Short term (up to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐14.33, 9.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Serum vitamin k levels <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Short term (up to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.46 [‐12.65, 3.73]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">1 mg versus 5 mg oral vitamin k</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008482.pub6/references#CD008482-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008482.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008482-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008482-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008482-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008482-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008482-note-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD008482-note-0013">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008482-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008482-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008482-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008482-note-0009">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008482-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008482\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008482\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008482\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008482\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008482\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008482.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008482.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008482.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008482.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008482.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728418960"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008482.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728418965"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008482.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec40509b49367',t:'MTc0MDcyODQxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 